Ketchum Eric S, Dickstein Kenneth, Kjekshus John, Pitt Bertram, Wong Meagan F, Linker David T, Levy Wayne C
Department of Medicine, University of Washington, USA.
Eur Heart J Acute Cardiovasc Care. 2014 Mar;3(1):46-55. doi: 10.1177/2048872613502283. Epub 2013 Sep 11.
Ischemic heart disease is a leading worldwide cause of death. The Seattle Post Myocardial Infarction Model (SPIM) was developed to predict survival 6 months to 2 years after an acute myocardial infarction with evidence of left ventricular dysfunction.
A total of 6632 subjects from the EPHESUS trial were used to derive the predictive model, while 5477 subjects from the OPTIMAAL trial were used to validate the model. Cox proportional hazards modeling was used to develop a multivariate risk score predictive of all-cause mortality. The SPIM risk score integrated lab and vital parameters, Killip class, reperfusion or revascularization, the number of cardiac evidence-based medicines (aspirin, statin, β blocker, ACEI/ARB, aldosterone blocker), and the number of cardiac risk factors. The model was predictive of all-cause mortality after myocardial infarction, with an AUC of 0.75 at 6 months and 0.75 at 2 years in the derivation cohort and 0.77 and 0.78 for the same time points in the validation cohort. Model predicted versus Kaplan-Meier observed survival was excellent in the derivation cohort. It remained so in the validation cohort--84.9% versus 85.0% at 2 years. The 10% of subjects with the highest predicted risk had approximately 25 times higher mortality at 2 years than the 10% of subjects with the lowest predicted risk.
The SPIM score was a powerful predictor of outcomes after myocardial infarction with left ventricular dysfunction. Its highly accurate predictions should improve patient and physician understanding of survival and may prove a useful tool in post-infarct risk stratification.
缺血性心脏病是全球主要的死亡原因。西雅图心肌梗死后期模型(SPIM)旨在预测急性心肌梗死后6个月至2年且伴有左心室功能障碍证据的患者的生存率。
来自依普利酮预防心肌梗死长期评估研究(EPHESUS)试验的6632名受试者用于推导预测模型,而来自心肌梗死后缬沙坦疗效评估研究(OPTIMAAL)试验的5477名受试者用于验证该模型。采用Cox比例风险模型来制定预测全因死亡率的多变量风险评分。SPIM风险评分整合了实验室及生命体征参数、Killip分级、再灌注或血运重建情况、心脏循证药物(阿司匹林、他汀类药物、β受体阻滞剂、血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂、醛固酮受体阻滞剂)的使用数量以及心脏危险因素的数量。该模型可预测心肌梗死后的全因死亡率,在推导队列中,6个月时的曲线下面积(AUC)为0.75,2年时为0.75;在验证队列中,相同时间点的AUC分别为0.77和0.78。在推导队列中,模型预测的生存率与Kaplan-Meier观察到的生存率吻合度很高。在验证队列中也是如此——2年时分别为84.9%和85.0%。预测风险最高的10%受试者在2年时的死亡率比预测风险最低的10%受试者高出约25倍。
SPIM评分是左心室功能障碍心肌梗死后预后的有力预测指标。其高度准确的预测结果应能提高患者和医生对生存率的认识,并且可能成为心肌梗死后风险分层的有用工具。